公开(公告)号：US20060019272A1

公开(公告)日：2006-01-26

申请号：US11122329

申请日：2005-05-03

申请人： Mark Geraci ,  Todd Bull ,  Norbert Voelkel ,  Christopher Coldren

发明人： Mark Geraci ,  Todd Bull ,  Norbert Voelkel ,  Christopher Coldren

IPC分类号： C12Q1/68

CPC分类号： G01N33/6893 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2800/12 ,  G01N2800/321

摘要： Disclosed are methods to diagnose a patient that has a pulmonary disease, and particularly, pulmonary arterial hypertension, using biomarkers that are differentially regulated in the peripheral blood cells of patients with such disease as compared to individuals that do not have the disease. Also disclosed are methods to diagnose a patient that has idiopathic pulmonary arterial hypertension as compared to pulmonary arterial hypertension associated with secondary causes. Pluralities of nucleotides and antibodies useful in the invention are described. Methods of identifying compounds with the potential to treat pulmonary arterial hypertension (PAH) are also described.

摘要翻译： 公开了使用与患有该疾病的个体相比，在患有这种疾病的患者的外周血细胞中差异调节的生物标志物来诊断具有肺部疾病，特别是肺动脉高血压的患者的方法。 还公开了与与次要原因相关的肺动脉高压相比，诊断具有特发性肺动脉高压的患者的方法。 描述了可用于本发明的多种核苷酸和抗体。 还描述了鉴定具有治疗肺动脉高压（PAH）潜力的化合物的方法。

公开(公告)号：US20070270505A1

公开(公告)日：2007-11-22

申请号：US10587052

申请日：2005-01-24

申请人： Paul Bunn Jr. ,  Christopher Coldren ,  Wilbur Franklin ,  Mark Geraci ,  Barbara Helfrich ,  Fred Hirsch ,  Razvan Lapadat ,  Michio Sugita ,  Samir Witta

发明人： Paul Bunn Jr. ,  Christopher Coldren ,  Wilbur Franklin ,  Mark Geraci ,  Barbara Helfrich ,  Fred Hirsch ,  Razvan Lapadat ,  Michio Sugita ,  Samir Witta

IPC分类号： A61K31/00 ,  A61P35/00 ,  C12Q1/02 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136

摘要： Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

摘要翻译： 公开了鉴定，提供和使用一组生物标志物，其预测对吉非替尼和其他EGFR抑制剂的敏感性或抗性，以及与之相关的产品和过程。 具体地说，描述了一种用于选择预期从治疗性施用EGFR抑制剂，其激动剂或具有与EGFR抑制剂具有实质上相似的生物学活性的药物中受益的癌症患者的方法。 还描述了鉴定与EGFR途径相互作用以允许或增强对EGFR抑制剂的反应性的分子的方法，以及用于检测指示EGFR抑制剂的敏感性或抗性的基因表达的多种多核苷酸或抗体 ，其激动剂，或具有与EGFR抑制剂基本相似的生物学活性的药物。 还描述了鉴定具有增强EGFR抑制剂功效潜力的化合物的方法。

公开(公告)号：US20060276546A1

公开(公告)日：2006-12-07

申请号：US11421873

申请日：2006-06-02

申请人： Robert Keith ,  Mark Geraci ,  York Miller

发明人： Robert Keith ,  Mark Geraci ,  York Miller

IPC分类号： A61K31/557

CPC分类号： A61K31/5585 ,  A61K31/557

摘要： The present invention provides a method for preventing or reducing the risk of cancer or the progression of premalignant dysplasia in a subject having a higher risk factor by administering a therapeutically effective amount of prostacyclin analog.

摘要翻译： 本发明提供了通过施用治疗有效量的前列环素类似物来预防或降低具有较高危险因素的受试者的癌症风险或恶变前发育不良进展的方法。